Publications
37
Citations
612
Est. group size
—
Recurring co-author estimate
Active years
18
Publishing since 2009
Typically publishes in teams of ~6 · 15% small-team papers (≤3 authors) · across 10 venues
- GDTR: Layer-wise Settling Depth Reveals Biological Grammar in Genomic Foundation Models
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Representative vs. Load-bearing Layers: A Dissociation in Genomic Foundation Models
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Membrane association of active genes organizes the chloroplast nucleoid structure
Proceedings of the National Academy of Sciences · 2024
- The association between tooth brushing during lunchtime and obesity in South Korean adolescents
Scientific Reports · 2024
- First in-human, intracisternal dosing of RGX-111, an investigational AAV gene therapy, for a 21-month-old child with mucopolysaccharidosis type I (MPS I): 3.5 year follow-up
Molecular Genetics and Metabolism · 2024
- Retrospective Natural History Study of neurodevelopment in neuronopathic Mucopolysaccharidosis Type II
Medical Research Archives · 2024
- Daily living skills on the Vineland Adaptive Behavioral Scale version 2 (VABS-II) in neuronopathic mucopolysaccharidosis type II (MPS II)
Molecular Genetics and Metabolism · 2023
- RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in human study
Molecular Genetics and Metabolism · 2023
- The relationship between the expanded neuronal ceroid lipofuscinosis 2 (CLN2) clinical rating scale for motor function (CLN2 CRS-MX) and GAITRite® parameters
Molecular Genetics and Metabolism · 2023
- RGX-121 gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in human study
Molecular Genetics and Metabolism · 2023
- Quantifying and modelling disease progression trajectory for natural history of MPS II
Molecular Genetics and Metabolism · 2023
- Beyond the normative data: Understanding the Mullen Scales of Early Learning (MSEL)
Molecular Genetics and Metabolism · 2022
- RGX-121 gene therapy for the treatment of severe mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in-human study
Molecular Genetics and Metabolism · 2022
- RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in-human study
Molecular Genetics and Metabolism · 2022
- Identification of a biomarker that differentiates neuronopathic forms of MPS I and MPS II
Molecular Genetics and Metabolism · 2022
- Molecular Genetics and Metabolism×16
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Proceedings of the National Academy of Sciences×1
- The Counseling Psychologist×1
- Scientific Reports×1
- Allison M. Bradbury
Medicine · The Ohio State University
- Molly McPheron
Medicine · Indiana University
- Mark Roberts
Medicine · University of Michigan
- James A. Shayman
Medicine · University of Michigan
- Emily de los Reyes
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile